MDMA, the active compound in ecstasy, is generally detectable in urine for roughly two to four days after a single dose when tested with standard laboratory methods, but one of its major metabolites can show up for considerably longer. In controlled human studies, the metabolite HMMA remained detectable in urine for a median of about five and a half days after a single dose, with some individuals still testing positive past six days. The actual window for any given person depends on the dose taken, the sensitivity of the test used, and individual differences in metabolism.
What Controlled Studies Show
The most direct evidence comes from studies where volunteers received known doses of MDMA and then provided urine samples at regular intervals. In one such study, participants received low and high doses of MDMA (1.0 and 1.6 mg/kg) under clinical supervision. After the high dose, the parent drug MDMA was last detected in urine roughly 35 hours earlier than its metabolite HMMA, which had a median last detection time of about 131 hours, or around five and a half days. In some participants, HMMA remained detectable as long as 157.8 hours after dosing, which works out to about six and a half days. Several participants were still testing positive for MDMA itself at the time they were discharged from the study facility.1PubMed Central. Urinary MDMA, MDA, HMMA, and HMA Excretion Following Controlled MDMA Administration to Humans
These numbers paint a more nuanced picture than the “two to three days” you often hear. That shorter window is a reasonable estimate for the parent compound detected by a standard screening test, but it undersells the persistence of metabolites. When laboratories test specifically for HMMA, the window stretches well beyond what most people expect. Whether this matters depends on the kind of test being administered.
What Gets Excreted and Why It Matters for Testing
When you take MDMA, your body does not simply pass it through unchanged. The drug is broken down into several products, and these metabolites are what labs often look for. MDMA is excreted as the unchanged parent drug alongside MDA (its demethylated form) and the metabolites HMMA and HMA, both of which appear in urine in free form and as glucuronide or sulfate conjugates.2Journal of Analytical Toxicology. Urinary MDMA, MDA, HMMA, and HMA Excretion Following Controlled MDMA Administration to Humans Of these, HMMA is the most abundant metabolite in urine and the one with the longest detection window, which is why some drug-testing protocols now specifically target it.
A standard workplace or probation drug screen typically uses an immunoassay panel that looks for amphetamine-type substances broadly. These tests are designed to flag the parent compound and closely related molecules, so they pick up MDMA and MDA quite well. But HMMA, despite being the most plentiful metabolite, does not always trigger the immunoassay in the same way. Specialized confirmation tests using mass spectrometry can detect all of these substances at very low concentrations and distinguish them precisely.
Why Higher Doses Do Not Simply Mean Proportionally More Drug
One of the less intuitive aspects of MDMA pharmacology is that the relationship between dose and blood levels is not linear. Double the dose does not mean double the amount of drug circulating in your system; it can mean far more than double. Research in animal models has shown that when the dose was increased from a low to a moderate level, blood levels of MDMA rose roughly threefold, and at the next step up they rose tenfold compared to the baseline dose, far exceeding what a simple doubling or tripling would predict.3PubMed Central. Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat
This disproportionate buildup happens because MDMA inhibits the very enzyme responsible for breaking it down. As you take more, the enzyme gets increasingly saturated and unable to process the drug efficiently. The practical consequence is that a person who takes a large dose, or who redoses during the same session, will likely have MDMA in their system for noticeably longer than someone who took a modest amount. It also means that the difference between a “moderate” and a “heavy” session may be much larger in terms of detection window than the difference in the number of pills consumed would suggest.
How Genetics Shape the Detection Window
MDMA is primarily metabolized by an enzyme called CYP2D6, which is notoriously variable across the population. Some people carry gene variants that make this enzyme highly active, while others are what geneticists call “poor metabolizers” with little to no functional enzyme. A pooled analysis of eight controlled studies involving 139 healthy participants found that poor metabolizers had peak MDMA concentrations about 15% higher than typical metabolizers. Their levels of the active metabolite MDA were about 50% higher, while the inactive metabolite HMMA was 50 to 70% lower.4PubMed Central. CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals
On the surface, a 15% bump in peak concentration sounds modest, and it is. The reason is the autoinhibition effect mentioned above: because MDMA shuts down its own metabolizing enzyme, everyone who takes a typical recreational dose effectively becomes a poor metabolizer for a while, regardless of their genetic starting point. Researchers have described this as “phenocopying,” meaning the drug temporarily makes everyone’s metabolism look the same.5PubMed Central. MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? As a result, genetics matter less for MDMA than for many other drugs processed by the same enzyme. In practical terms, the dose you took and whether you redosed are more reliable predictors of how long you will test positive than any genetic quirk.
That said, genetics can still influence the ratio of metabolites in your urine. One study found that among typical metabolizers, those carrying two fully functional copies of the CYP2D6 gene produced significantly higher plasma levels of HMMA compared to those with only one functional copy.6PLoS ONE. Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT) This shifts the pattern of what a lab would see in a urine sample, which could theoretically affect detection when a test targets a specific metabolite rather than the parent drug.
Stereochemistry as a Forensic Clock
MDMA exists in two mirror-image forms, called R and S enantiomers. Your body handles these two forms at different speeds, and the ratio between them in urine changes over time in a predictable way. Research has shown that in the five days following a dose, the R/S ratio shifts steadily, with certain metabolites becoming enriched in one form over the other. Investigators have proposed that measuring these enantiomer ratios could help estimate when someone actually took the drug, improving the interpretation of urine results in forensic and clinical settings.7PubMed Central. Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans
This is a niche application, mostly relevant in legal disputes where the timing of ingestion matters, but it illustrates something useful about how MDMA detection works: the same urine sample can be read in different ways depending on how sophisticated the analysis is. A basic immunoassay gives you a yes-or-no answer. A confirmation test tells you which specific substances are present and in what amounts. And a chiral analysis, though rarely ordered, can estimate when the drug was consumed. Each layer adds resolution.
False Positives and the Limits of Screening Tests
Immunoassay-based drug screens are fast and inexpensive, but they have known weaknesses. The antibodies used in amphetamine and MDMA panels are not perfectly selective, and some legitimate medications can trigger false-positive results. Research has found that certain immunoassay kits for amphetamines and MDMA are prone to false positives because the antibody recognizes structurally similar molecules that have nothing to do with recreational drug use.8PubMed Central. One Hundred False-Positive Amphetamine Specimens Characterized by Liquid Chromatography Time-of-Flight Mass Spectrometry
One documented example involves fenofibrate, a cholesterol-lowering medication. Its primary metabolite, fenofibric acid, was shown to cross-react on a commercially available ecstasy immunoassay, producing a false-positive result at the standard screening cutoff of 500 ng/mL.9Journal of Analytical Toxicology. Fenofibric Acid Can Cause False-Positive Urine Methylenedioxymethamphetamine Immunoassay Results If you are taking a prescription medication and test positive on an initial screen, request a confirmation test. Laboratories performing forensic or workplace testing are generally required to confirm a positive screen with mass spectrometry before reporting the result.
How Confirmation Tests Work
When a screening test flags a sample, the next step is a confirmatory analysis that can identify and quantify specific drugs with high precision. Modern methods use liquid chromatography coupled with tandem mass spectrometry, which can separate and measure MDMA, MDA, and other amphetamine-type substances simultaneously. Validated methods detect MDMA at concentrations as low as 0.2 ng/mL and MDA at 1 ng/mL, far below the typical immunoassay cutoff.10PubMed. Fast LC-MS/MS method for the determination of amphetamine, methamphetamine, MDA, MDMA, MDEA, MBDB and PMA in urine These techniques are sensitive enough to be applied across biological matrices including blood and hair in addition to urine.11Forensic Science International. Simultaneous analysis of six amphetamines and analogues in hair, blood and urine by LC-ESI-MS/MS
The practical takeaway is that if you are subject to confirmation testing rather than a simple point-of-care screen, the detection window effectively shifts in one direction only: longer. The cutoff thresholds for these instruments are vastly lower than what a standard immunoassay looks for, meaning traces of MDMA or its metabolites that would fly under a screening test’s radar will show up clearly on confirmatory analysis. Some testing protocols also specifically analyze for HMMA in urine, which as noted above can persist for close to a week.12Journal of Analytical Toxicology. Mixed-Mode Solid-Phase Extraction Procedures for the Determination of MDMA and Metabolites in Urine Using LC-MS, LC-UV, or GC-NPD
Does the Sample Degrade Over Time?
A separate question from how long MDMA stays detectable in your body is how stable it remains in a collected urine sample. This matters in legal and forensic contexts, where there can be days or weeks between sample collection and analysis. Stability testing has demonstrated that MDMA and the related compounds MDA and MDEA show no significant degradation in urine stored at various temperatures for at least 21 weeks.13Forensic Science International. Stability study of the designer drugs “MDA, MDMA and MDEA” in water, serum, whole blood, and urine under various storage temperatures In other words, a urine sample that tests positive immediately after collection should still test positive months later if stored properly. Delays in getting the sample to a lab do not create a loophole.
How Urine Compares to Other Testing Methods
Urine is the most common matrix for MDMA detection, but it is not the only one. Blood testing gives a narrower window, typically 24 to 48 hours, because MDMA clears from the bloodstream faster than from urine. Oral fluid (saliva) testing captures a similarly short window and is commonly used in roadside testing for impaired driving. One controlled study collected plasma, oral fluid, and sweat samples in parallel with urine during the first five hours after MDMA administration, confirming that concentrations appear in all of these matrices almost immediately.14PubMed. Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions
Hair testing operates on a completely different timescale. MDMA and its metabolites are incorporated into the hair shaft as it grows, and because hair grows at a roughly predictable rate, a section of hair can reveal drug use from months earlier. Hair testing is far less common for MDMA than urine testing, but it does come up in certain legal, child custody, and forensic investigations. One case report involving an infant exposed to MDMA illustrated the forensic value of measuring both parent drug and metabolites: the child’s hydrolyzed urine showed MDMA at 11.7 mg/L and HMMA at 34.4 mg/L, which helped clinicians confirm the exposure and determine its severity.15PubMed. 3,4-methylenedioxymethamphetamine (MDMA) intoxication in an infant chronically exposed to cocaine
Hydration, pH, and Other Folk Remedies
A common belief is that drinking large amounts of water before a test can flush MDMA from the system or dilute the sample enough to produce a negative result. Drinking excessive water does dilute urine, and very dilute samples can fall below a test’s cutoff concentration. But modern drug-testing programs check for this. Labs routinely measure urine creatinine and specific gravity, and a sample that is too dilute gets flagged as “substituted” or “dilute,” which typically means you have to retest under observed conditions. Some programs treat a dilute sample as presumptively positive.
Urine pH can also influence the excretion rate of amphetamine-type substances. Acidic urine promotes faster clearance, while alkaline urine slows it. This is a real pharmacological effect, and it is one reason the detection window varies between individuals even at the same dose. However, deliberately acidifying your urine through diet or supplements is neither reliable nor safe enough to meaningfully shorten a detection window. The effect is modest compared to the factors of dose and metabolism, and attempting it can cause real harm to your kidneys.
Practical Numbers for Common Scenarios
Pulling together the controlled-study data and accounting for test sensitivity, here is a rough guide to what you might expect under different circumstances:
- Standard immunoassay screen: a single moderate dose of MDMA will likely produce a positive result for about one to three days, depending on dose size and individual metabolism.
- Confirmation testing for parent MDMA: because the detection threshold is far lower, the window extends to roughly three to four days for a single moderate dose.
- Metabolite-specific testing (HMMA): the window stretches to about five to six days at the median, with outliers exceeding six and a half days after a single high dose.
- Heavy or repeated dosing: the nonlinear metabolic accumulation effect means the window can extend well beyond these single-dose estimates. No controlled study has administered the multi-pill doses common in some recreational settings, so the upper bound is genuinely unknown.
These windows assume a single use event in someone who does not use MDMA regularly. Chronic use builds up drug and metabolite concentrations in body tissues, though controlled studies of chronic dosing are understandably rare.
Why the Evidence Is Mostly From Small Studies
Nearly all the precise detection-window data comes from studies conducted in controlled clinical settings, where the doses are measured, the participants are screened for health conditions, and urine is collected at fixed intervals. These studies involve small numbers of volunteers, typically 10 to 15 per study, because giving a Schedule I substance to humans requires extensive ethical review and regulatory approval. The advantage is precision: every milligram is accounted for, and the timing is exact. The limitation is that the doses used in these studies tend to be lower than what many people take recreationally, and they typically involve a single dose rather than the redosing pattern that is common at parties or festivals.
Real-world detection windows are likely longer, on average, than what the controlled studies report. Higher doses trigger more autoinhibition, alcohol and other co-ingested substances can alter metabolism, and sleep deprivation and dehydration, both common in recreational settings, affect kidney function and urine concentration. The controlled-study numbers are a floor, not a ceiling, for the detection window in a typical recreational scenario.